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ABSTRACT
AN EVALUATION OF THE COSTS AND HEALTH BENEFITS ASSOCIATED WITH AN OVERSEAS
VOLUNTARY HIV SCREENING PROGRAM FOR REFUGEES UNDERGOING RESETTLEMENT TO THE
UNITED STATES
By
MICHELLE CANADY
JULY 24, 2015

Since 2010, HIV screening is no longer required as part of the overseas medical
examination for U.S.‐bound refugees. Estimated HIV prevalence for U.S‐bound refugees range
from 0% to 9%, with an average of 2.2%. Based on this data, many refugees may be at high risk
for HIV and HIV‐associated infections and sequelae when compared to the 0.4% to 0.9%
prevalence range in the U.S. population. The Centers for Disease Control and Prevention (CDC)
believes that some refugees are also not being screened during health assessments after arrival
in the U.S. These missed opportunities are creating a concerning public health gap in HIV
diagnosis and early linkage to care. Given the uncertainty and potentially high prevalence in
refugees bound for the U.S., it is important to consider the need and impact of overseas HIV
screening interventions.
This capstone is an economic analysis of costs associated with an overseas voluntary HIV
screening and treatment program for refugees undergoing resettlement to the U.S. There is a
gap in the literature with regard to the costs to screen refugees for HIV either overseas or in the
United States. This study seeks to close that gap by answering the following question:
 Will HIV screening for refugees overseas be less expensive for the U.S. government than
domestic screening and will early screening have positive public health outcomes?
The results of this study suggest that HIV screening for refugees overseas will be less
expensive for the U.S. government than domestic screening and early screening will have a
positive effect on public health outcomes for refugees and receiving communities. Initiating
the proposed intervention should provide cost‐savings to the U.S. government each year.
Increasing the rates of overseas screening should increase the number of refugees screened
and linked to care at least 3 months earlier. Early screening and linkage to care is in line with
both the U.S. National HIV Strategy and the United Nations High Commissioner for Refugees
(UNHCR) recommendations, resulting in positive health benefits to U.S.‐bound refugees and the
receiving communities. For U.S.‐bound refugees with HIV, health benefits of implementing the
proposed overseas intervention would include increased life expectancy and quality of life;
delayed onset of AIDS and opportunistic infections; and reduced transmission of HIV.
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INTRODUCTION
Refugees are people that have been forced to seek refuge outside of their country of nationality
due to fears of persecution (DOS, 2014a). Each year, 50,000 to 70,000 refugees resettle to the U.S.
(CDC, 2015a). Refugee populations are exceptionally vulnerable to disease outbreaks and profound
health disparities (CDC, 2009; Pattie, Janakiram, Topp, and McCarthy, 2007; Szajma and Ward, 2015).
They frequently fall through health jurisdictional gaps, lacking health-care services from their countries of
origin and finding themselves outside the priorities of their host countries (Dr. Weinberg, personal
communication, January 12, 2015).
Refugee populations are at risk for TB, HIV, numerous vaccine-preventable diseases, neglected
tropical diseases, parasitic infections, obesity, diabetes, mental health issues, nutritional deficiencies, and
chronic hepatitis B infection (Edberg, 2010; Eckstein, 2011; Walker et al., 2013; CDC, 2012a). The risks
vary by refugee population and camps. For example the prevalence of pathogenic parasitic diseases
ranges from 8% to 86% in refugees resettled to the U.S. (CDC, 2013a). The reason for the large range
may be due to differences in living conditions, geographic location, age, previous exposures, and diet
(CDC, 2013a).
Refugees in camps often face health issues that are magnified by crowded living conditions and
limited access to health care (CDC, 2013b). These conditions can facilitate outbreaks of infectious
disease among the vulnerable populations in the camps (CDC, 2013b). Since 2008, more than 50
outbreaks of communicable diseases, including measles, mumps, varicella, hepatitis E, polio and cholera
have occurred; many were preventable outbreaks of vaccine-preventable diseases and diseases
attributable to inadequate safe water and sanitation (Weinberg, Personal Communication, August 25,
2014).
The human immunodeficiency virus (HIV) remains an important public health challenge around
the world, affecting the health of many populations including refugees. Globally, over 35 million people
are living with HIV (CDC, 2013c). A great amount of progress has been made in the fight against HIV,
but new infections occur each year affecting the lives of many individuals. In 2013, 2.1 million people
were diagnosed with new infections illustrating the pervasive nature of the epidemic (CDC, 2013c).
Estimated HIV prevalence rates for U.S-bound refugees range from 0% to 9%, with an average of 2.2%

1

(Dr. Klosovsky, personal communication, January, 25, 2015). Based on this data, many refugees may be
at high risk for HIV and HIV associated infections and sequelae when compared to the 0.4% to 0.9%
prevalence range in the U.S. population (UN AIDS, 2014).
Since 2010, HIV screening is no longer required as part of the overseas medical examination for
U.S.-bound refugees. CDC believes that some refugees are also not being screened during health
assessments after arrival in the U.S. (Dr. Weinberg, personal communication, January 12, 2015). These
missed opportunities are creating a concerning public health gap in HIV diagnosis and early linkage to
care. Given the uncertainty and potentially high prevalence in refugees bound for the U.S., it is important
to consider the need and impact of overseas HIV screening interventions.
This study is an economic analysis of costs associated with an overseas voluntary HIV screening
and treatment program for refugees undergoing resettlement to the U.S. There is a gap in the literature
with regard to the costs to screen refugees for HIV either overseas or in the U.S. This study seeks to
close that gap by answering the following question:


Will HIV screening for refugees overseas be less expensive for the U.S. government than
domestic screening and will early screening have positive public health outcomes?
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LITERATURE REVIEW
Biology of Human Immunodeficiency Virus (HIV)
“The human immunodeficiency virus (HIV) is a retrovirus that infects cells of the immune system,
destroying or impairing their function (WHO, 2014a).” Transmission of HIV can occur through unprotected
sexual intercourse (anal or vaginal), transfusion of contaminated blood, sharing of contaminated needles,
and between a mother and her infant during pregnancy, childbirth and breastfeeding (WHO, 2014a). As
the infection progresses, the immune system becomes weaker, and the person becomes more
susceptible to opportunistic infections (WHO, 2014a). CD4 positive (CD4+) T cells are destroyed as HIV
attacks the immune system, leaving HIV-infected people susceptible to other diseases, infections, and
complications (NIAID, 2012a). CD4 count is often used to measure the level of impaired immune
function. Most healthy people have CD4 counts of around 800 to 1,200 (NIAID, 2012a). Often HIVinfected persons do not develop any serious symptoms for several years, but as the CD4 count declines
serious symptoms and other opportunistic infections can occur (NIAID, 2012a).
Progression of HIV
There is a well-documented progression for HIV (AIDS.gov, 2013). Progression through the
stages of HIV differ based on multiple factors including genetic makeup, age, health before infection, subtype of infection, co-infection with other viruses, timeliness of diagnosis and linkage to care, adherence to
treatment regimens, and health practices (AIDS.gov, 2013). The stages of HIV infection are:
1)

Acute Infection – flu like symptoms occur within two to four weeks after infection, called
“acute retroviral syndrome” (ARS) or “primary HIV infection.” During this stage there is a
very high risk for transmission to sexual or drug using partners (AIDS.gov, 2013).

2)

Clinical Latency – symptoms are not produced while the infection is living or developing,
sometimes called “asymptomatic HIV infection” or “chronic HIV infection.” Transmission
is still possible during this stage of the disease (AIDS.gov, 2013).

3)

Acquired Immunodeficiency Syndrome (AIDS) – most advanced stage of HIV, when
an HIV-infected person’s CD4 count drops below 200 or they have developed one or
more opportunistic infections (AIDS.gov, 2013).

Opportunistic infections (OIs) are common in HIV-infected individuals, because they take
advantage of the weakened immune system (AIDS.gov, 2010). They can be local, systemic, or spread
across the body (AIDS.gov, 2010). Susceptibility is often associated with the CD4 count level (AIDS.gov,
3

2010). HIV treatment often increases the CD4 count helping to protect against OIs (AIDS.gov, 2010).
CDC has compiled a list of more than 20 OIs that define AIDS including: candidiasis of bronchi, trachea,
esophagus, or lungs; invasive cervical cancer; coccidioidomycosis; cryptococcosis; cytomegalovirus
disease; histoplasmosis; isosporiasis; kaposi's sarcoma; mycobacterium avium complex; tuberculosis;
pneumocystis carinii pneumonia; progressive multifocal leukoencephalopathy; salmonella septicemia;
and toxoplasmosis of the brain (AIDS.gov, 2010).
Diagnosing HIV
HIV screening is an effective method to identify new HIV infections and to link patients to care
and treatment (WHO, 2014a). Early diagnosis reduces high-risk behaviors in HIV positive patients
resulting in reduced transmission. (WHO, 2014b). Screening includes a comprehensive approach that
includes administering HIV diagnostic tests, delivering the test results, conducting pre- and post-screen
counseling to encourage behavior change, and linkage to care if needed (WHO, 2013). Diagnostic
testing refers to the administration of the blood tests and the laboratory process to identify the presence
or absence of HIV infection (NIH, 2013).
HIV screening programs have been successful in diagnosing new cases of HIV infections over
the course of the epidemic. One clear example is the success in using screening to diagnose HIV in
pregnant women and using prevention methods to reduce transmission from mother-to-infant.
Implementation of recommendations for universal prenatal HIV screening, treatment and prevention
strategies have resulted in a 95% decrease in perinatal AIDS cases in the U.S. since 1992 (Mofenson et
al., 2006). In addition, screening programs led to a decline in the risk for perinatal transmission from an
HIV-infected mother to less than 2% (Mofenson et al., 2006).
Diagnostic Tests
Diagnostic tests for HIV include rapid antibody assay tests and confirmatory tests through
enzyme-linked immunosorbent assay (ELISA) and the Western blot (Understanding Health, 2015). Blood
testing can detect HIV through the presence or absence of antibodies in the blood (WHO, 2014b). During
the first three to six weeks of infection, the antibodies are being produced in the body and are not yet
detectable by the tests that are currently available (WHO, 2014a; NIAID, 2009). Transmission can occur
at all stages of infection, but the greatest risk is during this early period (WHO, 2014a).
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HIV Screening Guidelines
Different global and domestic organizations have developed recommendations and guidelines
with regards to HIV screening. Among these organizations, the most applicable to this study are the
World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC). These
organizations have revised their recommendations over the years as new testing methods and
information on risk, transmission, and treatment for HIV became available.
World Health Organization
WHO first issued guidance on HIV screening, referred to as HIV testing and counseling (HTC),
soon after HIV tests were first developed in 1985. WHO currently recommends that HIV screening should
be voluntary and not mandated or coerced and the patient should have the right to decline screening
(WHO, 2012). WHO issued subsequent guidance that included the five components that should be used
in administering HIV screening (WHO, 2012). The five components are consent, confidentiality,
counseling, correct test results, and connection/linkage to prevention, care, and treatment (WHO, 2012).
United States
CDC’s HIV screening recommendations have been revised many times since the first guidelines
were issued in 1985. The history of these guidelines and revisions are described below.


1985: The U.S. Public Health Service, now a part of the CDC recommended screening of
donated blood or plasma, shortly after HIV was identified as the cause of AIDS and an HIV
antibody test was approved. With limited knowledge of the disease in the beginning of the
epidemic, the goal of HIV screening was to protect the blood supply (Branson et al., 2006).



1987: As the impacts of positive HIV serology became evident, CDC issued guidelines for
HIV prevention, including counseling and testing as a priority strategy for persons at high risk
and recommended routine screening of those seeking STD treatment (Branson et al., 2006).



1993: After the approval of the first rapid test for HIV in 1992, CDC recommended extending
voluntary counseling and screening to include hospitalized patients, emergency departments,
and outpatients in acute-care hospital settings (Branson et al., 2006).



1994: CDC recommended counseling for people with high-risk behaviors include clientspecific prevention goals and strategies (Branson et al., 2006).



1995: With demonstrated evidence of treatments that substantially reduce perinatal
transmission of HIV from mother-to-infant, CDC recommended routine counseling of all
pregnant women to encourage voluntary HIV screening (Branson et al., 2006).



2001: CDC revised recommendations to include HIV screening in routine prenatal care,
5

simplify screening procedures, and encourage flexibility of the consent process. CDC also
extended HIV screening recommendations in health-care settings to include more types of
providers to increase access and flexibility of HIV counseling and screening. The guidelines
include routinely offering screening to all patients in high HIV-prevalence settings and
targeted risk-based screening in low prevalence settings (Branson et al., 2006).



2006: CDC revised guidelines to include routine “opt-out” screening for all patients age 13 to
64 in all health care settings, including all pregnant women and annual screening for those at
high-risk (Branson et al., 2006).

Treating HIV
While a cure does not yet exist for HIV or AIDS, treatment can slow the progression of HIV
(AIDS.gov, 2013). Treatment reduces the HIV viral load in the body, preserves CD4 levels, and
dramatically slows the destruction of the immune system (NIAID, 2012b). Current U.S. recommendations
are to begin treatment upon diagnosis of HIV, regardless of CD4 count, to reduce the risk of disease
progression (NIH, 2014). HIV screening and treatment can have many positive impacts on the lives of
infected individuals and communities. Earlier diagnosis and linkage to care and treatment can lead to
increased life expectancy and quality of life; delayed onset of AIDS and opportunistic infections; and
reduced transmission of HIV.
With treatment, an HIV-infected person can live an almost normal lifespan and often never
progress to AIDS (AIDS.gov, 2013). Vermund (2006) concludes that “the typical HIV-infected person now
receiving potent combination ART lives at least 13–14 years longer than if he or she were to forego this therapy
or if it were otherwise unavailable.” Unfortunately early diagnosis does not always happen and some

people are diagnosed with HIV and AIDS at the same time (AIDS.gov, 2013). On average, the clinical
latency stage lasts about 10 years for people not on treatment, but can progress more quickly (AIDS.gov,
2013). Often people who progress to AIDS without treatment only survive about 3 years and only about 1
year with an opportunistic infection (AIDS.gov, 2013).
Research shows that HIV treatment can also reduce the spread of HIV to others (AIDS.gov,
2013). The United States Preventive Services Task Force (USPSTF) found that knowing positive HIV
status reduces transmission through reduced high risk behaviors (USPSTF, 2013). In 2011, the HIV
Prevention Trials Network (HPTN) randomized clinical trial found that early HIV treatment reduced the risk
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of sexual transmission of HIV, in heterosexual couples, to an uninfected partner by 96% (CDC, 2013c).
The USPSTF found that approximately 60 infected people would need to be treated to prevent 1 death
from HIV infection after 3 years (USPSTF, 2013). Given these significant benefits of early treatment,
screening and early linkage to care is critical. To this end, the national HIV/AIDS strategy has a goal to
increase the proportion of HIV-infected individuals linked to care within three months of diagnosis
(Branson et al., 2006).
Prevalence of HIV
Globally
AIDS and HIV infections have had a cataclysmic impact on the global community, with some
countries being far more impacted than others. Over the course of the epidemic, 35 million people have
died and 70 million have been infected with HIV (WHO, 2014a). Worldwide, HIV prevalence is estimated
at 0.8% in adults aged 15 to 49 years old (WHO, 2014a). However, the burden of HIV varies greatly
across regions and countries (WHO, 2014a). For example, the most significantly affected area in the
world is sub-Saharan Africa with nearly 1 in every 20 adults living with HIV (WHO, 2014a).
United States
The AIDS epidemic has also impacted the health and lives of millions of people in the U.S. where
more than 1.2 million people in 2011 were living with HIV (CDC, 2013c). Approximately 50,000 new
infections occur each year in the U.S. (CDC, 2013c). These new infections are disproportionately
affecting specific groups of Americans, including gay and bisexual men, African American men and
women (CDC, 2013c), foreign-born individuals, and African foreign-born individuals (Prosser, Tang, &
Hall, 2012). The medical burden of HIV is exacerbated by the fact that about 20% of people living with
HIV do not know they are infected and may unknowingly pass the virus to others (NIAID, 2009b).
According to the CDC, a high-prevalence setting is a geographic location or community with an
HIV prevalence of at least 1% (Branson et al., 2006). These settings include sexually transmitted disease
(STD) clinics, correctional facilities, homeless shelters, tuberculosis clinics, clinics serving men who have
sex with men, and adolescent health clinics with a high prevalence of STDs (Branson et al., 2006).
Branson et al., 2006 found that more frequent screening would benefit those patients who are known to
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be at higher risk for HIV infection, actively engaged in risky behaviors, and live in a high-prevalence
setting (Branson et al., 2006).
U.S.-Bound Refugees
There is very limited literature published on HIV prevalence or incidence in refugee populations.
Further, the studies that exist tend not to be applicable across all refugees because they are limited to
specific regions of the world, refugee camps, or refugee populations. The most comprehensive data for
all U.S.-bound refugees is from 2009, so it may not be reflective of the current state of HIV in refugees
resettling to the U.S. The findings of the studies and data reviewed are summarized below.


Congolese Refugees in 2013: A recent CDC study found a 6% prevalence rate after screening
176 refugees (Ms. Russell, personal communication, November, 10, 2014)



Refugees Resettling to the U.S. in 2009: An analysis, by the International Organization for
Migration (IOM), of refugees screened prior to resettlement found an average prevalence of
4.1%, ranging from 0% to 9.0% by country (Dr. Klosovsky, personal communication, January 25,
2015)



Refugees Resettling to New Zealand: Nisbet et al. (2007) found a 1.3% prevalence in refugees
settling to New Zealand over an 11 year time frame



Refugee Arrivals to Minnesota from 2000 to 2007: A study by Lowther et al. (2012) found a
0.9% prevalence rate



African Refugees Resettling to France: Bouree et al. (1995) found a 6.3% prevalence rate
based on data from a three year period

Given the uncertainty and potentially high prevalence in refugees bound for the U.S., it is important to
consider the need and impact of HIV screening interventions for refugees resettling to the U.S.
Overview of Refugee Resettlement to the U.S.
Through the U.S. Refugee Admissions Program (USRAP), the U.S. offers resettlement to
approximately 50,000 to 70,000 refugees annually (CDC, 2015a). This U.S. program is considered a
critical component of federal government efforts to shield vulnerable refugee populations displaced by
political events around the globe (DOS, 2013). “A refugee is defined as any person who is outside his or
her country of nationality who is unable or unwilling to return to that country because of persecution or a
well-founded fear of persecution based on the alien's race, religion, nationality, membership in a particular
social group, or political opinion (UNHCR, 1951).”
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In 1950, the United Nations General Assembly established the Office of the United Nations High
Commissioner for Refugees (UNHCR) to coordinate international protection and support of refugees
worldwide (UNHCR, 2015b). “According to UNHCR, there are 15.4 million refugees around the world,” of
which almost half are in Asia and about 28% are in Africa. (DOS, 2014a; UNHCR, 2015). Living
conditions vary widely for refugees around the world, ranging from established refugee camps to living in
urban areas (UNHCR, 2015). In camps, refugees usually have access to some basic health care services
provided by non-governmental organizations working with UNHCR; however, in urban areas, the
refugees may not have access to any routine health care or other support services, such as food rations
(Dr. Weinberg, personal communication, January 12, 2015).
Resettlement is considered one of three possible “durable solutions” for refugees (DOS, 2014a).
The other durable solutions: repatriation to their country of origin and local integration into the host
country, are considered more desirable than resettlement. Often repatriation is not a feasible option
because the conflict from which they fled continues to be prevalent in their home country (DOS, 2014a).
Many times local integration in the host country is difficult due to economic, social, and political
challenges (DOS, 2014a). Many refugees would prefer to return to their home countries, but for many it
is not possible (UNHCR, 2015b). Millions of refugees spend decades in refugee camps, unable to return
home (USCRI, 2015). Resettlement in another country is often the only way refugees have a chance to
rebuild their lives (USCRI, 2015).
Historically, U.S. policy has admitted refugees of special humanitarian concern. The first refugee
legislation was the Displaced Persons Act of 1948, following World War II, authorizing the admission of
400,000 displaced Europeans (Refugee Council USA, 2015). Future laws followed allowing people,
escaping from countries with Communist leadership, from Hungary, Poland, Yugoslavia, Korea, China,
and Cuba to resettle to the U.S. (Refugee Council USA, 2015). Over the years, many private and
religious organizations have assisted with refugee resettlement, a model that has continued into the
current U.S. refugee resettlement program (Refugee Council USA, 2015). Congress passed the Refugee
Act of 1980, which provides the legal basis for today’s USRAP (Refugee Council USA, 2015).
During its history, the USRAP has responded to changing circumstances. For example, the end
of the Cold War shifted from bigger groups of refugees in select areas to resettlement of refugees from
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many countries around the world (DOS, 2014b). “In 2013, the USRAP admitted refugees of over 69
nationalities who began their journeys in some 92 countries (DOS, 2013).”
The U.S. has the largest resettlement program of any country around the world. “Since 1975,
Americans have welcomed over 3 million refugees from all over the world. Refugees have built new lives,
homes and communities in towns and cities in all 50 states” (DOS, 2014a). In fiscal year 2014, an
estimated 69,500 refugees arrived in the U.S. (DOS, 2014b). Every year, the President, in consultation
with Congress, sets a ceiling for the number of refugees to be resettled and specifies the geographic
areas from which they should come. For example, the FY 2015 Presidential request specifies a ceiling of
70,000, with approximately 46,000 from Asia and 17,000 from Africa (DOS, 2014b).
Refugees come to the U.S. in a legal “refugee” status, allowing them to work and receive special
support and services, such as refugee medical assistance (DOS, 2014b). One year after arrival, they are
eligible to adjust to lawful permanent resident status (green card holders) and, after 5 years, they can
become U.S. citizens (DOS, 2014b). The program is considered a public-private partnership with the
premise that refuges should become economically self-sufficient as quickly as possible (DOS, 2013).
Social services are available to refugees for up to five years after arrival, including employment services
such as English language and vocational training to assist refugees to obtain employment and enhance
their long-term career opportunities (DOS, 2014b).
Resettlement is a complex, multi-agency process including the Department of State (DOS), the
Department of Homeland Security (DHS), and the Department of Health and Human Services (HHS).


Department of State (DOS), Bureau of Population, Refugees, and Migration (PRM)
o

Works with UNHCR to identify refugees that should be considered for
resettlement, manages policies on admission, and directs the overseas
processing of refugees (DOS, 2014b).

o

Funds physicians to conduct the required medical examinations overseas (CDC,
2014a).

o

Coordinates transportation, reception, and integration of refugees to the U.S.
(DOS, 2014b).



Department of Homeland Security (DHS)
o

Makes determinations on refugee status abroad, conducts security clearances
for refugee processing, and adjusts citizenship status of refugees (DOS, 2014b).
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Department of Health and Human Services (HHS)
o

The Office of Refugee Resettlement (ORR) provides assistance to refugees after
arrival in the U.S. through grants to state and local programs, in collaboration
with voluntary organizations known as Resettlement Agencies, which help newly
arrived refugees settle into local communities (DOS, 2014b).

o

CDC provides technical guidance for medical screening for refugees prior to and
after arrival in the U.S. (CDC, 2014a).

Health of Refugees
Health Care for U.S.-Bound Refugees
“The Secretary of the HHS has statutory responsibility for preventing the introduction,
transmission, and spread of communicable diseases into the U.S. (42 U.S. Code § 264). The authority
for carrying out these functions has been delegated to CDC’s Division of Global Migration and Quarantine
(DGMQ). DGMQ works to fulfill this responsibility through a variety of activities, including the
establishment of standards for medical examination of persons destined for the U.S. (ExpectMore.Gov,
2008).” These activities include development, coordination, and oversight of disease screening programs
for immigrants and refugees (CDC, 2013b).
DGMQ plays a critical regulatory and public health role in the USRAP. Currently CDC provides
technical and regulatory oversight to medical screening and identifies high risk refugee populations for
major public health causes of morbidity and mortality for U.S. state and local public health follow-up
(Expectmore.gov, 2008). DGMQ has the technical expertise and connections, including Regional Field
Programs in Nairobi and Bangkok, to work overseas with health partners in refugee camps, provide
oversight for the required overseas medical exam, and coordinate with state and local health department
refugee programs and clinics for better continuity of care and program alignment (Dr. Weinberg, personal
communication, January 12, 2015).
In addition, DGMQ developed the Quality Assessment Program (QAP) to monitor the quality of
the overseas examination and ensure the validity and thoroughness of the health assessment (CDC,
2015b). Through QAP, DGMQ provides technical guidance to the overseas panel physicians who
perform the medical screening examination at over 760 sites (CDC, 2015b). DGMQ teams, with medical
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and laboratory expertise, perform on-site visits and make recommendations to sites on how to improve
any deficiencies identified during the visit (CDC, 2015b).
Medical Examinations for U.S.-bound and Newly Arrived Refugees
Before resettlement, refugees undergo a required medical examination overseas governed by the
technical requirements developed by DGMQ (CDC, 2014a). DOS/PRM subcontracts with physicians
from the International Organization for Migration (IOM) to conduct the required medical exam (CDC,
2015b). After arrival, a domestic health assessment is recommended, but not required (CDC, 2013d).
Refugees are eligible for eight months of refugee medical assistance, which is provided by ORR and
administered by state refugee programs (DOS, 2014b). Some refugees are also eligible for Medicaid
(DOS, 2014b). Local and state governments provide additional funding to support these assessments
and follow-up care (DOS, 2014b). The first domestic health assessment usually occurs within 30 to 90
days after arrival (CDC, 2013d).
The required overseas medical exam for refugees focuses on the detection and treatment of
“inadmissible conditions” as defined by regulations in Section 212(a)(1)(A) of the Immigration and
Nationality Act (INA) (CDC, 2014b). “Inadmissible conditions” include TB, syphilis, chancroid, gonorrhea,
granuloma inguinale, lymphogranuloma venereum, and Hansen's Disease (leprosy) (CDC, 2014b). The
examination includes a medical history, physical examination, and screening and diagnostic testing
(CDC, 2014b).
Previous experience demonstrated that more flexibility, beyond a fixed list of diseases, is needed
to allow for rapid response to emerging disease outbreaks (CDC, 2014b). To address this need, CDC
revised the scope of the medical exam in 2005 for specific situations requiring additional medical
screening, testing and treatment for the following disease categories:


“Quarantinable diseases designated by any Presidential Executive Order.
o

Current diseases include: cholera, diphtheria, infectious tuberculosis, plague, smallpox,
yellow fever, viral hemorrhagic fevers, severe acute respiratory syndrome (SARS), and
influenza caused by novel or re-emergent influenza (pandemic flu).



Events that are reportable as a public health emergency of international concern (PHEIC) to the
World Health Organization (WHO) under the International Health Regulations (IHR) of 2005
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o

Currently polio, smallpox, SARS, influenza, and other public health emergencies of
international concern) (CDC, 2014b).”

A risk-based approach, based on medical and epidemiological factors, is now used to define the
additional medical screening, testing, and treatment required (CDC, 2014b). The medical and
epidemiologic factors considered are the potential public health impact, dynamics of the emergence of the
disease, risk of spread to the U.S., transmissibility and virulence of the disease, pathogenic factors
threatening U.S. health security, and impacts based on the geographic location of the medical
examinations (CDC, 2014b).
The medical exam is valid for six months unless the refugee has active or inactive tuberculosis
infection, in which case the exam is only valid for three months (DOS, 2015). The shortened validity is to
reduce the risk of active tuberculosis in higher risk persons (DOS, 2015). If the exam validity expires
before the refugee is able to travel to the U.S., the medical exam must be repeated (DOS, 2015).
Refugees who have an inadmissible condition must undergo treatment before resettlement (DOS, 2015).
The treatment is provided by IOM and paid for by DOS/PRM (DOS, 2015).
Unfortunately the required medical examination for resettlement does not address many
important public health issues (Walker, Stauffer, and Barnett, 2013). Refugees are vulnerable
populations who are often neglected and underserved, and many have not had access to adequate
health care and prevention services for years (Pottie et al., 2007; Szajma & Ward, 2015). They are
exceptionally vulnerable to disease outbreaks and profound health disparities and frequently fall through
the health jurisdictional gaps, lacking health-care services from their countries of origin and falling outside
the priorities of their host countries (Dr. Weinberg, personal communication, January 12, 2015).
Refugee populations are at risk for TB, HIV, numerous vaccine-preventable diseases, neglected
tropical diseases, parasitic infections, obesity, diabetes, mental health, nutritional deficiencies, and
chronic hepatitis B infection (Edberg, 2010; Eckstein, 2011; Walker et al., 2013; CDC, 2012b). The risks
vary by refugee population and camps, for example the prevalence of parasitic diseases that are
pathogenic ranges from 8% to 86% in refugees resettled to the U.S. (CDC 2013a). The reason for the
large range may be due to differences in living conditions, geographic location, age, previous exposures,
and diet (CDC 2013a).
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Refugee Health Assessments for Newly Arrived Refugees
CDC recommends that refugees undergo a medical health assessment as soon as possible after
arrival to the U.S. (CDC, 2012a). CDC provides guidelines for state public health departments and
medical providers to carry out the assessments (CDC, 2013d). Currently, CDC’s HIV guidelines for
screening refugees after arrival to the U.S. are consistent with CDC’s general HIV screening
recommendations (CDC, 2012c). CDC also recommends that information about HIV testing, results,
diagnosis, and care should be provided in native languages and culturally sensitive methods (CDC,
2012c). CDC estimates approximately 95% of refugees are being screened for HIV, after arrival to the
U.S., as a part of this health assessment (Ms. Lee, personal communication, October 12, 2014). Even
with this high rate of acceptance, screening is happening at least three months later than it would if it
were performed overseas. This delay extends the time it takes for diagnosis and initiation of care and
treatment, in turn increasing the risk of transmission to others.
Refugee Health and HIV: A Critical Public Health Gap
Since January 4, 2010, HIV screening is no longer required for refugees during the overseas
medical examination, because HIV is preventable and is not spread through casual contacts (CDC,
2012c). The change was made to address the public health knowledge gained about HIV and the way it
spreads since it was added as an inadmissible condition in 1987 (CDC, 2014a). The removal of HIV as
an inadmissible condition for immigration to the U.S. was consistent with global recommendations and
policies that sought to remove HIV-status to restrict migration.
Even though HIV screening is no longer required as part of the medical examination, refugees
can still be screened if they provide consent (CDC, 2014b). However, the guidance from CDC to
physicians conducting the examination is to no longer screen for HIV, but that they can advise refugees
on screening if it is clinically indicated (CDC, 2013b). CDC did not initially encourage routine HIV
screening due to the potential stigma and discrimination that may have occurred soon after the removal of
the mandatory screening (Dr. Weinberg, Personal Communication, January 15, 2015). Refugees can be
considered inadmissible to the U.S. on the basis of “public charge” which means if they are likely to
become dependent of the government for subsidence or long-term care. Even though public charge is
not supposed to be considered for treatment of infectious diseases, there was concern that discrimination
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could occur due to stigma (USCIS, 2014). Currently only around 2% of refugees overseas are screened
for HIV prior to resettling to the U.S., so many refugees are not aware of their HIV status prior to resettling
to the U.S. (Dr. Klosovsky, personal communication, January 25, 2015). Due to this low acceptance rate,
the removal of the required screening has left a critical public health gap to be addressed.
Several states have provided CDC with examples that illustrate the negative impact of refugees
arriving without knowledge of their HIV status and being linked with appropriate care and treatment. For
example, in North Carolina a Congolese refugee died four months after arriving to the U.S. due to HIVrelated causes, just 10 days after receiving his HIV diagnosis (Dr. Shetty, personal communication,
November 5, 2014). In Colorado, almost 90 days after arrival to the U.S., a single nursing mother of five
tested positive for HIV (Dr. Shetty, personal communication, November 5, 2014). Fortunately the child
tested negative for HIV and nursing was stopped to eliminate the risk of the baby being infected (Dr.
Shetty, personal communication, November 5, 2014). Illinois also had experience with two refugee
women that did not learn of their HIV positive status until after giving birth (Dr. Shetty, personal
communication, November 5, 2014). In these examples, HIV screening overseas may have allowed the
refugees to have earlier awareness of their status, access to care and treatment, and continuity of care
after arrival to the U.S., thus reducing the likelihood for poor health outcomes and transmission to their
loved ones.
Opportunities exist for screening refugees for HIV before and after arrival to the U.S. CDC is
considering implementing a public health intervention to increase access to voluntary counseling and
testing in refugees prior to arrival in the U.S., during the required medical examination (Mr. Dalal,
personal communication, November 29, 2014). CDC believes enough time has passed that this will no
longer be a concern if physicians were encouraged to increase acceptance of HIV screening in refugees
prior to arrival in the U.S. (Dr. Weinberg, personal communication, January 15, 2015). The proposed
intervention would be aimed at addressing the critical gap in screening for HIV in refugees prior to coming
to the U.S.
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Pertinent differences in foreign-born, African-born, and refugee populations in HIV disease transmission,
progression, and treatment adherence
Limited research is available comparing foreign-born, African-born, refugees, and U.S.-born
populations about HIV disease related factors. The literature that is available reviews differences in HIV
transmission, disease progression, adherence to treatment protocols, and health outcomes among
foreign-born, African-born, refugees compared to U.S.-born populations. The findings applicable to this
study are described below.


Routes of Transmission: The literature suggests that rates of heterosexual transmission of HIV
are higher in foreign-born and refugee populations than in U.S.-born populations.
o

39.4% among foreign-born versus 27.2% for U.S. born individuals (Prosser et al., 2012)

o

New infections are four times higher among African-born residents than the general U.S.
population (Blanas et al., 2013).

o

81% of refugees reported heterosexual transmission as the primary risk factor for HIV as
opposed to 60% in the U.S.-born population (Beckwith et al., 2008).



Disease Progression: Blanas et al. (2013) found that Africans with HIV in the U.S. are often
diagnosed at a later stage of infection with lower CD4 counts and higher rates of AIDS versus
U.S.-born and most other foreign-born groups. They are also more likely to develop AIDS within
12 months of diagnosis as compared to U.S.-born Blacks (45% versus 37%).



Initiation of Treatment: A study by Blanas et al. (2013) found that African-born populations may
be more likely to initiate care within three months of diagnosis (76%) versus U.S.-born
populations (72%).



Mortality and Survival Rates: Even though African foreign-born are often diagnosed at later
stages of disease, they appear to be more likely to have lower mortality and longer survival rates.
o

African-born populations appear to have lower mortality rates associated with HIV than
U.S.-born populations, 7.1 per 1,000 per year versus 19.5 per 1,000 per year respectively
(Blanas et al., 2013).

o

An earlier analysis by Blanas et al., 2013 found slightly higher survival rates among
foreign-born versus U.S.-born blacks one year (87% versus 85%) and three years (82%
versus 75%) after AIDS diagnosis.

o A possible hypotheses for these differences are the combination of the persistence of the
healthy immigrant effect with a high level of initiation and retention in care (Blanas et al.,
2013). The healthy immigrant effect is a widely accepted phenomenon where immigrants
in the U.S. have better health when compared to U.S.-born populations, even though
they come from countries with higher morbidity and mortality rates and is not affected by
socio-economic factors (e.g., education or income) (Kennedy et al., 2006).
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Costs of HIV Screening in the United States
There are very few economics or cost studies of U.S. routine opt-out HIV screening in health care
settings (e.g., emergency departments, primary care settings, urgent care centers, and STD clinics). The
studies are structured so that they capture different components and therefore the cost results vary widely
depending on settings and strategies for implementing screening. Because the studies are structured so
differently, their component results (e.g., costs of screening or counseling) are not comparable. Table 1
provides a summary of some of the findings in the literature.
Table 1: Review of selected U.S. HIV screening cost studies
Publication

Phillips et al.
(2000)

Mehta et al.
(2008)

Walensky et.
al (2005)

Costs

Year
Dollars

Incremental costper-HIV-case
$4,200
1999
Targeted screening
cost-per-HIV-case
$5,300

Personnel/labor
costs-per-HIV-case
identified
Range $1,980 to
$9,724

2004

Average per
positive screen
result $4,850
2002
Connect each HIV
case with care
$5,550

Explanation
Study examines two approaches to HIV screening, a targeted riskbased approach and a screen all approach. Using a survey of the
literature for input costs, the authors develop a cost effectiveness ratio
using a quality adjusted life year (QALY) measure as the outcome.
The study finds that routine screening of all patients costs less and
finds more cases of HIV than targeted screening. However, the
author’s note that targeted screening could be less expensive/more
effective in some populations.
Study examines the sociodemographics and behavioral risks of
voluntary HIV screening in five sites within the same medical center.
The study also publishes the personnel costs to administer HIV
screens, though does not include the costs of the test itself. The
primary driver behind the wide range in costs was the number of
screens-per-employee during an eight hour shift. Where there were
the fewest patients screened (emergency department), there were the
highest personnel costs-per-HIV case detected.
Study assesses identification of HIV cases in urgent care centers in
Massachusetts. The authors obtained program expenditures or
budgets, but from where and how is never explained in the
publication. There are cost results printed in the article, but an
explanation regarding the methods of calculation is not provided. With
the lack of methods for estimating costs in mind, it is unclear whether
the $4,850 for the test result should be added to the $5,550 to connect
HIV cases with care, or whether the less expensive value was for
patients diagnosed with HIV who were not connected with care.

One of the most pertinent studies for our purposes of determining HIV screening costs was
Pinkerton et al. (2010). The authors analyzed HIV screen costs in 45 U.S. hospitals and found that the
mean cost per test for rapid HIV screening in the U.S. is $48.07 for a negative test and $64.17 for a
preliminary positive test (in 2006 dollars), with counseling accounting for 38.4% of the total cost. Costs
were variable across hospitals and ranged from half to twice the estimates (Pinkerton et al., 2010). “The
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total cost of performing a rapid HIV test included the personnel costs associated with performing
counseling and screening-related procedures, the cost of the rapid-test kit, and the cost of miscellaneous
disposable materials. The cost of the rapid-test kits was obtained from the study surveys. The cost of
miscellaneous disposable items, such as latex gloves, sterile wipes and gauze pads, adhesive bandages,
phlebotomy equipment (needles, holders, blood tubes), absorbent workspace covers, biohazard wastedisposal bags, and laboratory supplies (pipettes, tubes) was estimated based on expert opinion at $1.50
per test (Pinkerton et al., 2010).”
Study Purpose
Since 2010, HIV screening is no longer required as part of the overseas medical examination for
U.S.-bound refugees. CDC believes that some refugees are also not being screened during health
assessments after arrival in the U.S. (Dr. Weinberg, personal communication, January 12, 2015). These
missed opportunities are creating a concerning public health gap in HIV diagnosis and early linkage to
care. Given the uncertainty and potentially high prevalence rates, ranging from 0 to 9%, in refugees
bound for the U.S., it is important to consider the need and impact of overseas HIV screening
interventions.
To address this public health gap, CDC is considering implementing an intervention to increase
the acceptance of opt-in voluntary HIV screening overseas for refugees, ages 13 to 64, prior to
resettlement to the U.S. Through this proposed strategy, the refugees would also be offered culturally
and linguistically-appropriate health education, counseling, and linkage to care and treatment.
Implementing this proposed strategy would ensure that USRAP applicants would have the opportunity to
learn their HIV status through an informed consent process that is completely voluntary. Those applicants
that screen positive could be started on treatment earlier, and then be linked in with appropriate medical
care and other needed services more quickly and efficiently after resettlement.
A review of the published literature found that no research compares the factors of interest in this
study for a population of refugees. There are no comparisons of the costs and benefits of overseas
versus domestic screening of refugees. This study is an economic analysis of costs associated with an
overseas voluntary HIV screening and treatment program for refugees undergoing resettlement to the
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U.S. This study seeks to close the gap in the literature, regarding the costs to screen refugees for HIV
overseas or in the U.S., by answering the following question:


Will HIV screening for refugees overseas be less expensive for the U.S. government than
domestic screening and will early screening have positive public health outcomes?

This study will provide unique information that can be used by the Division of Global Migration
and Quarantine at CDC to support increased budget requests to provide HIV screening for refugees while
they are still overseas. Like any other government organization, funding requests must be supported by
evidence of both effectiveness and thrift.

19

METHODS
In order to structure the project, I set up a series of meetings with subject matter experts (SME) at
the Centers for Disease Control and Prevention (CDC) in the Division of Global Migration and Quarantine
(DGMQ). Through these conversations I was able to outline the details of the proposed intervention and
the current state of HIV screening and treatment activities for refugees bound for the U.S. Further, the
SMEs provided guidance with regard to analytic options as applied to the epidemiology of HIV and the
options to conduct the economic analysis. Multiple meetings were conducted with SMEs to finalize the
assumptions and specifics of the proposed intervention to be used for this project’s analysis.
The list of SMEs consulted on the project are:


Dr. Michelle Weinberg, Medical Officer, expert in refugee healthcare and development
and implementation of public health programs in refugee populations



Dr. Brian Maskery, Economist, expert in economic health studies on refugees and
immigrant populations



Dr. Margaret Coleman, Economist, expert in economic health studies on refugees and
immigrant populations



Dr. Bill Stauffer, Medical Officer, expert in refugee healthcare in the U.S.



Dr. Alex Klosovsky, Medical Officer, expert in refugee health programs carried out by the
International Organization for Migration (IOM)



Mr. Warren Dalal, Public Health Advisor, expert in development and implementation of
public health programs in refugee populations



Ms. Deb Lee, Epidemiologist, expert in domestic refugee health programs



Dr. Sharmila Shetty, Medical Officer, expert in domestic refugee health programs

Describe the Proposed Intervention
Based on discussions with CDC SMEs, it was determined that the proposed intervention would
be to provide opt-in HIV screening overseas among the USRAP applicant population. Through this
proposed strategy, the refugees would also be offered culturally and linguistically-appropriate health
education, counseling, referrals to care and treatment, and voluntary screening for HIV. The proposed
intervention is analyzed in this paper at two patient acceptance rates to estimate potential cost savings
and health benefits. The 30% acceptance rate is referred to as “Option 1” and the 70% acceptance rate
is referred to as “Option 2”.
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Objectives
1) Increase the acceptance rate for voluntary opt-in HIV-screening overseas among the USRAP
applicant populations
2) Improve the continuum of care for those that are HIV-positive and ensure that follow-up in the
U.S. is made possible with accurate diagnostic information on HIV status
Program Components
The proposed intervention will introduce three main strategies to promote the knowledge of HIV status of
USRAP applicants:
1. Branding the concept of promotion of HIV screening as part of the overseas medical examination
process and an emphasis on mobilizing USRAP applicants to accept HIV screening
a. Mobilization will focus on the importance of knowing HIV status prior to resettlement to
the U.S. to reduce barriers to access appropriate medical services
b. Health education materials will be developed, that are culturally appropriate and
translated into native languages, to inform the refugees resettling to the U.S. of the
advantages of being screened overseas as well as additional TB tests that would be
required as part of the health exam process if the results are positive
2. Training staff to implement the new approaches to screening for HIV as part of the IOM medical
examination for USRAP applicants
3. Offer voluntary HIV screening for all USRAP applicants aged 13 to 64
Figure 1: Proposed intervention flow chart
“Know Before You
Go” Campaign
Promotion of HIV
Screening with a
focus on benefits of
screening as part of
the US medical
health
assessment—
preliminary
information session

PMTCT services
Accept HIV
Screen—
Receive
Counseling
Decline Screen: USRAP
applicant receives
brochure on importance
of knowing HIV status

Diagnostic

Post-screen
Counseling

If negative,
counsel on
importance of
prevention in the
U.S. context

If positive,
counsel and refer
for treatment.
Request further
TB tests.

Program Assumptions
In planning new interventions, assumptions are needed to analyze the potential impacts of
implementing the intervention. The following assumptions were used in the development of the proposed
intervention.
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Additional IOM capacity will be needed to implement this type of voluntary “opt-in” approach with
an enhanced focus on counseling/education to increase acceptance rates and to complete
care/treatment referrals



Training will be needed for new and current staff to implement the intervention



USRAP applicants will be offered HIV screening adhering to the below principles:



o

Informed Consent

o

Confidentiality

o

Appropriate and high quality pre- and post-screen counseling

o

Provision of correct screen results with proper quality assurance of the laboratories

o

Connection/linkage to prevention, care and treatment

Screening will be completed using a rapid HIV test and confirmation testing will be completed
using ELISA/Western Blot



Based on their front line experience with the uptake of medical protocols overseas, IOM
suggested the 2 acceptance rates of 30% (Option 1) and 70% (Option 2) for use in this study
o

Acceptance rates could be as low as 30%, because refugees may be resistant to HIV
screening due to concerns that a positive result may jeopardize resettlement and in some
countries being HIV positive carries tremendous social stigma



Costs associated with care/treatment referrals will be driven by the implementing partner (e.g.,
PEPFAR or host country programs)
o

The referral and treatment system is already established and being utilized for HIV
care/treatment referrals

o

Costs associated with care/treatment referrals and medication supplies are expected to be
covered by existing programs to which refugees will be referred by IOM



Countries have IOM laboratories already in place

Anticipated Health Outcomes
Implementing this proposed strategy would ensure that USRAP applicants would have the
opportunity to learn their HIV status through an informed consent process that is completely voluntary.
Those applicants that screen positive could be started on treatment earlier, and then be linked in with
appropriate medical care and other needed services more quickly and efficiently after resettlement.
Collect Data
The next step was to collect data in order to estimate HIV prevalence and the overseas and
domestic costs associated with HIV screening. Literature, internal CDC data, and information provided by
IOM were reviewed to identify the data available to estimate prevalence for this study. A literature review
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resulted in some cost estimates for screening in the U.S., but as explained earlier in the section titled,
“Costs in the U.S.” the studies were not comparable. Further, the study with the most complete costs
(Phillips et al., 2000) used inputs for screening that were taken from other studies and adjusted to 1999
dollars. So not only would these screening dollar values need to be adjusted again for this study to 2015
dollars, but they were also old and inflation adjustments become increasingly inaccurate with time.
Therefore, as explained in more detail below, the cost estimates in this study are based on prices in the
2015 Physicians’ Fee and Coding Guide (“the Guide,” 2015). IOM provided real-time actual data for the
costs to screen refugees overseas to that we could compare overseas and domestic costs for the same
processes.
Develop Study Model
A review of the published literature finds that no research compares the factors of interest in this
study for a population of refugees. There are no comparisons of the costs and benefits of overseas
versus domestic screening of refugees. All of the recently published models and studies would have to
be extensively modified to fit the refugee population and compare domestic and other country costs. For
example, a review of recent published research finds multiple studies that have used different methods
for assessing costs and cost-effectiveness of HIV screening and treatment including the Progression and
Transmission of HIV/AIDS Model (PATH), the Markov Model, and the Cost-Effectiveness of Preventing
AIDS Complication Model (CEPAC).
The PATH model was developed by CDC to “estimate lifetime measures and costs for HIVinfected individuals under different linkage to care models” (Gopalappa et al., 2012). The Markov model
tracks a cohort of individuals some of whom are already infected with HIV (Sanders et al., 2005). The
CEPAC model is a “widely published computer simulation of HIV disease and treatment…. [that]
simulates an HIV screening program and determines when each simulated HIV-infected patient will
become detected through screening or presentation of care with an AIDS-defining opportunistic infection
(OI)” (Paltiel et al., 2005). All of these models were created based on U.S. population parameters, so
modifications would have been required to adjust for any pertinent differences in HIV transmission,
disease progression, and other factors between refugee populations and U.S. populations. The
adjustment of these complex disease transmission models was beyond the scope of this project.
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Therefore, a program-cost model was developed for this project to analyze both HIV prevalence
and screening costs for Uganda, Ethiopia, and Kenya as compared with the domestic costs to perform
the same HIV screening. The outcome of interest is the comparison of the costs to provide HIV screening
overseas with costs for the same process in the U.S. based on different percentages of accepting
overseas and domestic HIV screening. Figure 2 provides a schematic of the model that is repeated for
each of the three countries: Uganda, Ethiopia, and Kenya. The model uses the average risk parameters
and costs. At the start of the model, either 30% or 70% of refugees accept screening overseas, and the
country-specific costs of screening are applied.


Those who accept screening overseas (30% or 70%): different percentages of refugees
are diagnosed as HIV free or HIV positive based on the country-specific prevalence
rates. Those who are HIV positive drop out of the model at this point and are assumed to
start treatment, ideally while still overseas. Those who are HIV negative arrive in the
U.S. where 20% are re-screened at the domestic cost. Those found HIV positive in the
U.S. go on to domestic treatment.



For those who do not accept screening overseas (30% or 70%): some percentage have
undiagnosed HIV but are never re-screened when they enter the U.S. 95% of the (30%
or 70%) persons who do not accept overseas screening are assumed to be screened in
the U.S. at domestic costs.
Figure 2: Model flow chart

Estimate Prevalence
The prevalence data collected was reviewed and analyzed for completeness and limitations were
identified so that the data could be reliably used in the model. Due to the changes in the USRAP lifting
requirements for HIV screening, HIV data in U.S.-bound refugee populations is largely not available after
2009. For example, HIV screening rates in the USRAP are currently very low at an estimated 2% by IOM,
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so it appears that this information may be unreliable. The limited data available in the literature are based
on small-sample CDC studies. All of the studies include very small numbers of refugees being screened.
Further the studies are limited to specific regions of the world, refugee camps, and/or refugee
populations. For example, a 2013 CDC study of Congolese refugees found a 6% prevalence based on
screening of 176 refugees. The prevalence data from these sources are insufficient to apply to the
current refugee population in the USRAP.
IOM provided 2009 USRAP HIV prevalence data by country as a potential data source for the
study. This data is the actual results from the last year of mandatory screening of refugees bound for the
U.S. or UNAIDS prevalence rates that were used as a proxy for countries where actual data was
unavailable. UNAIDS data was provided for 2 countries, Burundi, and Rwanda. Based on the review and
analysis of the available prevalence data sources, recommendations were discussed with the CDC
SMEs. Based on these discussions, it seemed that the most reliable data was the 2009 IOM data.
Therefore, a determination was made to use this dataset for estimating prevalence for this study. The
2009 IOM prevalence or UNAIDS proxy for each country was used in the model to determine the
estimated number of HIV positive individuals that would be diagnosed during screening.
Based on these 2009 data, U.S.-bound refugees from Sub-Saharan Africa prevalence ranged
from 1.3% (Burundi) to 9.0% (Uganda) (Dr. Klosovsky, personal communication, January 25, 2015).
These values are all higher, and in some cases much higher, than the worldwide average of 0.8 % and
the range of 0.4 to 0.9 % in the U.S. CDC recommends routine screening in all healthcare settings for the
general populations (ages 13 to 64) and annual screening for high-risk populations. According to CDC,
high-risk populations are geographic locations or communities with an HIV prevalence of at least 1%.
According to the CDC definition all of the sub-Saharan African refugee populations would be considered
high risk and routine and annual screening would be recommended.
IOM also provided estimates of the expected numbers of refugees that would be bound for the
U.S. in 2015 by country (Table 2). The data, in Table 2, is the prevalence and anticipated number of
refugees resettling to the U.S. in FY 2015 for the analysis for this study. The estimated numbers of HIVpositive refugees were multiplied by each acceptance rate to determine the estimated number of HIV
positive refugees identified for Option 1 (30% acceptance) and Option 2 (70% acceptance).
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Table 2: Estimated prevalence and positive cases for FY 2015 refugee arrivals
Country

2009
Prevalence1

UGANDA
TANZANIA
RWANDA*
SOUTH AFRICA
ETHIOPIA
KENYA
BURUNDI*
Countries Analyzed Summary6
Sub-Saharan Africa Summary7
USRAP Estimate Low Range8
USRAP Estimate High Range9

9.00%
4.01%
2.90%
2.42%
1.93%
1.38%
1.30%
4.10%
3.28%
2.24%
2.24%

360

Option 1
30% Acceptance
Rate
HIV+ Refugees4
108

Option 2
70% Acceptance
Rate
HIV+ Refugees5
252

1,500
2,500
2,500

60
73
61

18
22
18

42
51
42

5,000
6,000

97
83

29
25

68
58

2015
Estimated U.S.
Arrivals2

Estimated
HIV Positive
Refugees3

4,000

2,000

26

8

18

15,000

616

185

431

23,500

770

231

539

50,000
70,000

1,120
1,565

336
470

784
1,098

* UNAIDS HIV prevalence proxy
1 2009 prevalence rates provided by IOM, based on 2009 actual data for the USRAP or UNAIDS proxy data
2 FY 2015 estimated U.S. arrivals provided by IOM
3 Estimated HIV positive refugees calculated by multiplying the prevalence rate with the FY 2015 estimated arrivals
4 Option 1 calculated by multiplying the estimated HIV positive refugees by the acceptance rate of 30%
5 Option 2 calculated by multiplying the estimated HIV positive refugees by the acceptance rate of 70%
6 Summary results for 3 pilot countries: Uganda, Ethiopia, and Kenya
7 Sub-Saharan Africa reflects the estimates for all refugees bound for the U.S. from sub-Saharan Africa
8 Low range for the USRAP is estimated at 50,000 refugees bound for the U.S.
9 High range for the USRAP is estimated at 70,000 refugees bound for the U.S.

Identify Domestic Costs
After arriving in the U.S., refugees are currently accepting HIV testing at a rate of 95%. This
acceptance rate was used to estimate the domestic program costs for only screening refugees after they
arrive in the U.S. The acceptance rate was determined based on CDC SMEs estimation of the rate of
refugees currently screened after arrival to the U.S. The literature search did not produce reliable and/or
recent costs for HIV screening in the U.S.
For costs, in an online search, we were able to identify the Current Procedural Terminology codes
(CPT codes) that are universally used by all medical organizations (practices, clinics, and hospitals) to bill
for HIV screening. CPT codes are the universal language of medical billing used in the U.S. by any
medical organization that submits patient bills to any private insurance or public insurance such as
Medicare, or Medicaid. First, we looked online (Google) to find billing protocols for HIV screening. The
codes we found that are in routine use are shown in Table 3.

Table 3: CPT codes in routine use for HIV screening medical billing

CPT
Code
86701

Description
Test HIV 1*

Used in Model
(Yes or No)
Yes

Average
Costs
$92
26

86702
86703
86689
87390
99401
99402
36415

Test HIV 2
Test HIV 1 and 2
HIV Confirmatory Test
HIV 1 age, eia
15 minutes behavioral counseling to prevent STD*
30 minutes behavioral counseling to prevent STD*
Blood Draw*

No
No
Yes
No
Yes
Yes
Yes

$134
$136
$141
$96
$93
$155
$24

* Denotes codes and costs used in the model

We then went to the 2015 Physician’s Fee and Coding Guide to determine the costs associated
with the different CPT codes that had been recommended for billing in different medical organizations
guidance. The Physician’s Fee and Coding Guides are published annually after a nationally
representative survey of allowable billing charges in medical organizations. The results are arranged by
CPT code and provide a low and high allowable billing for private insurance as well as the Medicare
allowable billing charges for the same codes. Medicaid is not included because it is a state-based
program. After reviewing the ranges of allowable billing charges for different CPT codes that represented
components of the HIV screening process, it was decided to use the codes that had lower billing ranges.
These ranges were averaged to ensure that domestic costs were not overstated when compared with
overseas costs. The codes and costs used in the model to represent a typical domestic cost for HIV
screening are shown in Table 3. A formula was created to determine the U.S. cost-per-person for HIV
screening using the following steps:
1) The 86701 range for HIV testing seems to most closely match the values that appear in the
literature, so 100% of the average is used on the assumption that everyone who accepts
testing (30% or 70%) would get an initial test
2) 86689 seems to be the code of choice for confirmatory testing, we assign an average HIV
positive prevalence, based on the average for sub-Saharan Africa, of 3.2% ($141 X 3.2%)
3) We average the averages of 99401 and 99402 and assign 75% of that average to the total
cost (based on an assumption that approximately 75% of persons tested receive some sort of
risk assessment or counseling)
4) Add 100% of the blood draw 36415, assuming everyone who accepts testing would have a
blood draw

Using this formula and the average prevalence of 3.2% for sub-Saharan Africa,
$92+($141*3.2%)+((($93+$155)/2)*.75)+$24, the average domestic cost-per-person for HIV screening
was $214. The formula was used to calculate the U.S. domestic cost-per-person for each refugee
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population group analyzed (e.g., Uganda) based on the corresponding prevalence.
Identify Proposed Intervention Costs
The model uses country-specific budget and labor information provided by IOM to identify the
costs in Uganda, Ethiopia, and Kenya for screening and diagnosing a new HIV infection. Cost data
provided by IOM for the three pilot countries is based on caseload and the screening acceptance rates of
30% (Option 1) and 70% (Option 2). The costs are derived based on the additional support required to
implement the proposed opt-in HIV screening intervention.
The intervention has fixed costs that include staff (e.g., nurses and lab technicians), office
administrative staff, and training for staff. The fixed costs do not change based on the number of
refugees that accept HIV screening. Variable costs include laboratory consumables and patient support.
The patient support includes education materials, nutritional support, home visits, and pre-departure
evaluation. For Option 2 (70% acceptance rate) a 50% lab staffing adjustment is included to cover the
additional lab tests that will need to be performed.
These costs are calculated per refugee screened to determine the additional variable costs at
each screening acceptance level. In addition, overhead costs were included and calculated by IOM at a
rate of 5%. We did not explicitly include overhead in the domestic totals because it is implied in the
allowable billing charges. Costs were calculated based on screening acceptance rates of 30% and 70%
for each country (Table 4).
Table 4: Costs per country to implement the proposed HIV screening intervention
Budget Line
Kenya
Ethiopia
Uganda
Total
Caseload Population (# U.S.-bound refugees)
6,000
5,000
4,000
15,000
Fixed Costs1
$ 78,000 $ 46,800
$ 35,880
$ 190,680
Operational Costs2, Option 13
$ 24,713 $ 14,159
$ 10,000
$ 65,040
Operational Costs2, Option 24
$ 56,331 $ 42,037
$ 90,992
$ 179,359
Overhead, Option 1
$ 5,136
$ 3,548
$ 4,102
$ 12,786
Overhead, Option 2
$
6,717 $ 4,942
$ 6,844
$ 18,502
Total, Option 1
$ 107,849 $ 74,506
$ 86,150
$ 268,506
Total, Option 2
$ 141,047 $ 103,778
$ 143,716
$ 388,541
1 Fixed costs include staff (e.g., nurses and lab technicians), office administrative staff, and training for staff.
2 Operational costs include laboratory consumables and patient support
3 Option 1 is an acceptance rate of 30%
4 Option 2 is an acceptance rate of 70%

Assess Potential Health Benefits of the Proposed Intervention
The literature review documented that earlier HIV diagnosis and linkage to care and treatment
can result in increased life expectancy and quality of life; delayed onset of AIDS and opportunistic

28

infections; and reduced transmission of HIV. The comparison of the proposed intervention against the
current program identifies the number of new infections diagnosed and linked to treatment earlier. We
used the number of new cases to assess the extent of that public health impact. Results related to this
assessment are mostly qualitative, but when possible estimates of the health impacts were quantified.
According to the literature, early linkage to treatment has been shown to extend the lives of HIV
positive individuals by an estimated additional 13 to 14 years (Walensky et. al, 2006). The proposed
intervention would allow HIV positive refugees that opted for the test prior to arriving in the US to be
linked to care and treatment at least three months earlier than the current domestic only screening
program. We calculated the number of new infections that would be identified and linked to care at least
three months earlier overseas and compared the changes in timing of diagnosis. We then used the
number of new infections diagnosed from the modeling to determine the potential additional life-years that
could be saved for each refugee population (three country total, sub-Saharan Africa, and USRAP) at each
acceptance rate (Option 1: 30% and Option 2: 70%) for the proposed overseas HIV screening
intervention.
The literature also suggests that approximately 60 individuals starting treatment at a CD4 count of
500 could prevent 1 death from HIV infection after 3 years. We divided the number of refugees in each
population and acceptance rate that would start treatment earlier, likely at a higher CD4 count, by 60 to
provide a sense of the number of deaths from HIV infection that might be prevented after three years.
Since we cannot estimate CD4 counts for the new refugee infections diagnoses, this is a very crude
estimate that only illustrates potential benefits of the proposed overseas intervention.
Based on the literature review provided in section “Pertinent differences in foreign-born, Africanborn, and refugee populations in HIV disease transmission, progression, and treatment adherence,” it
appears that there are marked differences between African-born and U.S.-born in the stage at which HIV
is diagnosed and uptake of treatment post-diagnosis. African-born populations are diagnosed at later,
more critical stages but they are also more likely to follow treatment recommendations to try and maintain
their health. Therefore, if African-born refugees could be diagnosed earlier, CDC SMEs surmise that the
benefits to early diagnosis through screening might be even greater than we have estimated in the study.
Determine Results
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Cost Analysis
First, a comparison was completed to determine the cost differences between the proposed
overseas screening intervention and the current domestic program. The average costs-per-screen were
calculated for personnel, testing/processing, and training for each intervention. The results were used to
determine and compare the major cost drivers for each intervention.
Using the model and prevalence for each refugee population, we calculated costs-per-screen,
new infection, and total program costs for each intervention. The refugee populations include the three
countries (Uganda, Kenya, and Ethiopia), the average of the three countries, sub-Saharan Africa, and the
entire U.S. Refugee Admissions Program (USRAP). The interventions included were the proposed
overseas HIV screening intervention, at acceptance levels of 30% (Option 1) and 70% (Option 2), and the
current domestic HIV screening intervention. The costs were then compared to determine potential costsavings for the proposed intervention versus the current program.
A sensitivity analysis for the costs was conducted for Kenya and Uganda to determine the lowest
acceptance level of testing that would be cost saving. Kenya and Uganda were chosen because they
had the highest and lowest prevalence and estimated number of refugee arrivals. The model was used to
calculate and analyze the costs for implementing the HIV screening program at acceptance levels of 5,
10, 15, 20, and 25 percent. The associated savings or additional costs were analyzed to determine the
threshold of acceptance level to produce cost savings to the U.S. government.
Health Benefits Assessment
Based on a review of the literature, health benefits of early diagnosis and treatment of HIV were used to
assess and state the potential health benefits of the proposed overseas HIV screening intervention. The
estimated number of new infections identified was compared across the timeline of possible diagnosis of
the interventions. We also calculated life-years saved and deaths averted over three years for each
refugee population (total of three countries, sub-Saharan Africa, and USRAP) at each acceptance rate
(Option 1: 30% and Option 2: 70%) for the proposed intervention.
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RESULTS
Cost Analysis
Differences in Costs of Proposed Intervention and Current Program

The major cost differences between the proposed overseas screening intervention and the
current program are driven by personnel and testing supplies (Figure 3). Personnel includes costs for
staff (e.g., nurses and lab technicians), office administration, patient support, and a lab staffing
adjustment for Option 2 (70% acceptance). Testing/processing includes operational costs for laboratory
consumables. Training includes the additional training to implement the proposed intervention overseas.
Each category was then adjusted to include the 5% IOM overhead costs.


Overseas, the average costs per screen consist of personnel, testing/processing, and
training.






Option 1 (30% acceptance rate) total average costs per screen are $67, including:
o

$49 for personnel (73%),

o

$11 for testing/processing (17%), and

o

$7 for training (10%).

Option 2 (70% acceptance rate) total average costs are $34, including:
o

$28 for personnel (68%),

o

$8 for testing/processing (23%), and

o

$3 for training (9%).

Domestically, the average costs per screen consist of personnel and testing/processing.


The current program average costs per screen are $214, including:
o

$105 for personnel (49%) and

o

$109 for testing/processing (51%).

For all interventions the majority of the costs for screening are for personnel and
testing/processing, but these cost categories are much more expensive in the U.S. In the U.S., the
overall costs-per-screen are 2 to 5 times higher; personnel costs-per-screen are about 1 to 4 times
higher; testing/processing costs-per-screen have the most drastic differences at 9 to 13 times higher.
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Figure 3: Cost differences per screen by category and intervention acceptance level in
comparison with the current U.S. program

$214

$225
$200
$175

$109

$150
$125
$100

$67

$75

$11

$34

$49

$8
$23

Option 1 (30%)

Option 2 (70%)

$50
$25
$-

Personnel

Testing and Processing

$105

Current US Program
Training

Cost Analysis by Country
For all three countries analyzed (Uganda, Ethiopia, and Kenya), the costs for the current
domestic only HIV screening program are higher than the proposed overseas intervention at both
acceptance levels (30% and 70%). Cost-savings for the proposed intervention appear to be substantial
when compared to the current intervention.
Uganda
Figure 4 and 5 depict the model flow for each option for the proposed intervention in Uganda,
Option 1 (30% acceptance rate) and Option 2 (70% acceptance rate). Table 5 shows the cost
calculations using the model, with inputs of 4,000 refugee arrivals and 9% prevalence, for Option 1,
Option 2, and the Current HIV screening programs.

4000 enter for testing

Figure 4: Uganda cost analysis model – Option 1 (30% Acceptance)
91% HIV ‐

(20% of 91% are retested
USA) $221.69

30% tested OS $71.79
9% HIV + No further
screening

91% HIV ‐
70% untested OS

(95% are tested USA)
$221.69
9% HIV +
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4000 enter for testing

Figure 5: Uganda cost analysis model – Option 2 (70% Acceptance)

91% HIV ‐

20% of 91% are retested
USA $221.69

70% tested OS $51.33
9% HIV + No further
screening

91% HIV ‐
30% untested OS

95% are tested USA
$221.69
9% HIV +

Table 5: Cost calculations for Uganda refugee HIV screening program options
Option 1 - 30%
Acceptance
30 yes
70 no
Total

People
At Start
1200
2800
4000

Option 2 - 70%
Acceptance
70 yes
30 no
Total

People
At Start
2800
1200
4000

Current Domestic
Program
95% yes

People
At Start
3800

Overseas
Screening
Costs
$71.79

USA
Screening
Costs
$221.69

Overseas
Screening
Costs
$51.33

Overseas
Screening
Costs

USA
Screening
Costs

Initial
Screening
Costs
$86,150
$589,695

$221.69

Initial
Screening
Costs
$143,716
$252,727

USA
Screening
Costs
$221.69

Initial
Screening
Costs
$842,422

Rescreens
in USA
218

Rescreens
in USA
510

Rescreens
in USA

USA
Screening
Costs
$221.69

USA
Screening
Costs
$221.69

TOTAL
COSTS
$134,567
$589,695
$724,263
TOTAL
COSTS
$256,689
$252,727
$509,415

USA
Screening
Costs

TOTAL
COSTS
$842,422

Table 6 compares the costs of the proposed overseas screening intervention and the current
domestic screening. Using the model with inputs of 4,000 refugee arrivals and 9% prevalence, potential
total program cost-savings for the proposed overseas intervention when compared to the current
domestic intervention are:
o

Total Program Cost-Savings for Overseas Options compared to Domestic Screening
o Option 1 = $118,159 cost savings (14% reduction)
 Domestic costs at $842,422 minus Option 1 costs at $724,263
o Option 2 = $333,007 (40% reduction)
 Domestic costs at $842,422 minus Option 2 costs at $509,415
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Table 6: Cost comparison of proposed interventions versus the current program in Uganda
Costs
Cost Per Screen
Cost Per New Infection
Total Program Costs

Option 1
(30%)

Option 2
(70%)

Current
Program

$72
$798
$724,263

$51
$570
$509,415

$222
$2,463
$ 842,422

Cost Savings versus Current Program
Option 1
$
%
$150
68%
$1,666
68%
$118,159
14%

Option 2
$
%
$170
77%
$1,893
77%
$333,007
40%

Ethiopia
Figure 6 and 7 depict the model flow for each option for the proposed intervention in Ethiopia,
Option 1 (30% acceptance) and Option 2 (70% acceptance). Table 7 shows the cost calculations using
the model, with inputs of 5,000 refugee arrivals and 1.93% prevalence, for Option 1, Option 2, and the
Current HIV screening programs.

5000 enter for testing

Figure 6: Ethiopia cost analysis model – Option 1 (30% Acceptance)
98.07% HIV ‐

20% of 98.07% are
retested USA $221.72

30% tested OS $49.67
1.93% HIV + No further
screening

98.07% HIV ‐
70% untested OS

95% are tested USA
$221.72
1.93% HIV +

5000 enter for testing

Figure 7: Ethiopia cost analysis model – Option 2 (70% Acceptance)
98.07% HIV ‐

20% of 98.07% are
retested USA $221.72

70% tested OS $29.65
1.93% HIV + No further
screening

98.07% HIV ‐
30% untested OS

95% are tested USA
$221.72
1.93% HIV +
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Table 7: Cost calculations for Ethiopia refugee HIV screening program options
Option 1 - 30%
Acceptance
30 yes
70 no
Total

People
At Start
1500
3500
5000

Option 2 - 70%
Acceptance
70 yes
30 no
Total

95% yes

USA
Screening
Costs
$211.72

People
At Start
3500
1500
5000

Current Domestic
Program

Overseas
Screening
Costs
$49.67

People
At Start

Overseas
Screening
Costs
$29.65

Overseas
Screening
Costs

4750

USA
Screening
Costs

Initial
Screening
Costs
$74,506
$703,973

Rescreens
in USA
294

$211.72

Initial
Screening
Costs
$103,778
$301,703

USA
Screening
Costs
$211.72

Initial
Screening
Costs
$1,005,676

Rescreens
in USA
686

Rescreens
in USA

USA
Screening
Costs
$211.72

TOTAL
COSTS
$136,797
$703,973
$840,770

USA
Screening
Costs
$211.72

TOTAL
COSTS
$249,123
$301,703
$550,826

USA
Screening
Costs

TOTAL
COSTS
$1,005,676

Table 8 compares the costs of the proposed overseas screening intervention and the current
domestic screening. Using the model with inputs of 5,000 refugee arrivals and 1.93% prevalence,
potential total program cost-savings for the proposed overseas intervention when compared to the current
domestic intervention are:
o

Total Program Cost-Savings for Overseas Options compared to Domestic Screening
o Option 1 = $164,906 cost savings (16% reduction)
 Domestic costs at $1,005,676 minus Option 1 costs at $840,770
o Option 2 = $454,850 (45% reduction)
 Domestic costs at $1,005,676 minus Option 2 costs at $550,826

Table 8: Costs comparison of proposed interventions versus the current program in Ethiopia
Cost Savings versus Current Program
Costs
Cost Per Screen
Cost Per New Infection
Total Program Costs

Option 1
(30%)
$50

Option 2
(70%)
$30

Current
Program
$212

Option 1

Option 2

$

%

$

%

$162

77%

$182

86%

$2,574

$1,536

$10,970

$8,396

77%

$9,434

86%

$840,770

$550,826

$1,005,676

$164,906

16%

$454,850

45%

Kenya
Figure 8 and 9 depict the model flow for each option for the proposed intervention in Kenya,
Option 1 (30% acceptance) and Option 2 (70% acceptance). Table 9 shows the cost calculations using
the model, with inputs of 6,000 refugee arrivals and 1.38% prevalence, for Option 1, Option 2, and the
Current HIV screening programs.
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6000 enter for testing

Figure 8: Kenya cost analysis model – Option 1 (30% Acceptance)
98.62% HIV ‐

20% of 98.62% are retested
USA $210.95

30% tested OS $59.52
1.38% HIV + No further
screening

98.62% HIV ‐
70% untested OS

95% are tested USA
$210.95
1.38% HIV +

6000 enter for testing

Figure 9: Kenya cost analysis model – Option 2 (70% Acceptance)

98.62% HIV ‐

20% of 98.62% are retested
USA $210.95

70% tested OS $33.58
1.38% HIV + No further
screening

98.62% HIV ‐
30% untested OS

95% are tested USA
$210.95
1.38% HIV +

Table 9: Cost calculations for Kenya refugee HIV screening program options
Option 1 - 30%
Acceptance
30 yes
70 no
Total Costs
Option 2 - 70%
Acceptance
70 yes
30 no
Total Costs
Current
Domestic
Program
95% yes

People
At Start
1800
4200
6000
People
At Start
4200
1800
6000
People
At Start
5700

Overseas
Screening
Costs
$59.92

USA
Screening
Costs
$210.95

Overseas
Screening
Costs
$33.58

Overseas
Screening
Costs

USA
Screening
Costs

Initial
Screening
Costs
$107,849
$841,674

$210.95

Initial
Screening
Costs
$141,047
$360,717

USA
Screening
Costs
$210.95

Initial
Screening
Costs
$1,202,391

Rescreens
in USA
355

Rescreens
in USA
828

Rescreens
in USA

USA
Screening
Costs
$210.95

USA
Screening
Costs
$210.95

USA
Screening
Costs

TOTAL
COSTS
$182,741
$841,674
$1,024,415
TOTAL
COSTS
$315,797
$360,717
$676,514
TOTAL
COSTS
$1,202,391

Table 10 compares the costs of the proposed overseas screening intervention and the current
domestic screening. Using the model with inputs of 6,000 refugee arrivals and 1.38% prevalence,
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potential total program cost-savings for the proposed overseas intervention when compared to the current
domestic intervention are:
o

Total Program Cost-Savings for Overseas Options compared to Domestic Screening
o Option 1 = $177,976 cost savings (15% reduction)
 Domestic costs at $1,202,391 minus Option 1 costs at 1,024,415
o Option 2 = $525,877 (44% reduction)
 Domestic costs at $1,202,391 minus Option 2 costs at $676,514

Table 10: Costs comparison of proposed interventions versus the current program in Kenya
Costs
Cost Per Screen
Cost Per New Infection
Total Program Costs

Cost Savings versus Current Program

Option 1
(30%)

Option 2
(70%)

Current
Program

$60

$34

$211

$151

72%

$177

84%

$4,342
$1,024,415

$2,434
$676,514

$15,286
$1,202,391

$10,944
$177,976

72%
15%

$12,852
$525,877

84%
44%

Option 1
$
%

Option 2
$
%

Country Summary and Projections for Sub-Saharan Africa and the USRAP
The model was used with the following inputs (Table 11) to summarize the three country results and
estimate costs for sub-Saharan Africa, and the U.S. Refugee Admissions Program (USRAP).
Table 11: Refugee admissions and average HIV prevalence in refugee populations
Refugee Population

Number/
Prevalence

Three Country Summary (Uganda, Ethiopia, and Kenya)
Average Prevalence Estimate

4.10%

Estimated Refugee Admissions

15,000

Sub-Saharan Africa
Average Prevalence Estimate

3.28%

Estimated Refugee Admissions

23,500

US Refugee Admissions Program (USRAP)
Average Prevalence Estimate

2.24%

Low Range Estimated Refugee Admissions

50,000

High Range Estimated Refugee Admissions

70,000

Based on the model inputs outlined above, there would be significant annual total program costsavings for the proposed overseas intervention when compared to the current domestic intervention.
Table 12 outlines the estimated annual total program cost-savings for each refugee population (e.g.,
refugees bound for the U.S. from sub-Saharan Africa) for the 2 options (30% and 70% acceptance) of the
proposed intervention compared with the current domestic intervention.
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Table 12: Estimated total program cost-savings for the proposed intervention compared to the
domestic intervention by refugee population
Sub-Saharan
Africa1

Cost Savings

US Refugee Admissions Program
Low Range2

High Range3

Per screen4
Option 1 (in dollars)6

$146

$151

$165

reduction)6

68%

72%

78%

Option 2 (in
Option 2 (in percentage reduction)7

$177
82%

$179
85%

$185
88%

Option 1 (in dollars)6
Option 1 (in percentage reduction)6

$4,440
68%

$6,726
72%

$7,368
78%

Option 2 (in dollars)7

$5,405

$7,999

$8,278

82%

85%

88%

$657,163

$1,478,119

$2,371,633

14%

15%

17%

$1,977,756

$5,741,826

$6,309,634

41%

57%

45%

Option 1 (in percentage
dollars)7

Per new infection5

Option 2 (in percentage

reduction)7

Total program
Option 1 (in dollars)6
Option 1 (in percentage reduction)6
Option 2 (in

dollars)7

Option 2 (in percentage

reduction)7

1 Sub-Saharan Africa reflects the estimates for all refugees bound for the U.S. from sub-Saharan Africa
2 Low range for the USRAP estimated at 50,000 refugees bound for the U.S.
3 High range for the USRAP estimated at 70,000 refugees bound for the U.S.
4 Cost per screen for Option 1 and 2 reflects overseas cost per screen, domestic screening cost per screen is the same
as the current program
5 Cost per new infection for Option 1 and 2 reflects overseas cost per screen, domestic screening cost per screen is the
same as the current program
6 Option 1 is the proposed overseas screening intervention at the 30% acceptance rate
7 Option 2 is the proposed overseas screening intervention at the 70% acceptance rate

The following figures summarize the costs-per-screen (figure 10), per new infection (figure 11),
total program costs (figure 12). All of these summaries illustrate the significant cost-savings that could be
realized by implementing the proposed HIV screening overseas, even at a low acceptance level of 30%.
Figure 10: Summary of costs per screen by refugee population
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Figure 11: Summary of costs per new infection by refugee population
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Figure 12: Summary of total program costs by refugee population (in millions)
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Sensitivity Analysis for Kenya and Uganda
Table 13 (Kenya) and Table 15 (Uganda) represent the costs for acceptance levels of 5, 10, 15,
20, and 25 percent using the same prevalence and estimated refugee admission numbers for FY 2015.
Table 14 (Kenya) and Table 16 (Uganda) depict the additional costs or cost savings to the U.S.
government at each of these acceptance levels. Kenya and Uganda were used for this analysis because
they had the lowest and highest prevalence rates. Based on this analysis, implementing the proposed
intervention with acceptance levels below 10% in Kenya or Uganda may cost the U.S. government more
than the current U.S. domestic screening program. Currently CDC and IOM believe acceptance rates will
be 30% or higher, but the government would need to determine whether the health benefits outweigh the
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additional costs if the acceptance levels are below 10%. That said, it is widely accepted in the literature
that screening and early initiation into treatment is cost-effective and provides significant health benefits.
Table 13: Cost calculations for acceptance levels below 30% for Kenya
5%
Acceptance

People
At Start

30 yes
70 no
Total Costs

300
5700
6000

10%
Acceptance

People
At Start

70 yes
30 no
Total Costs

600
5400
6000

15%
Acceptance

People
At Start

70 yes
30 no
Total Costs

900
5100
6000

20%
Acceptance

People
At Start

70 yes

1200

30 no
Total Costs

4800
6000

25%
Acceptance

People
At Start

70 yes
30 no
Total Costs

1500
4500
6000

Current
Domestic
Program
95% yes

People
At Start

Overseas
Screening
Costs
$290.33

Overseas
Screening
Costs

USA
Screening
Costs
$210.95

Initial
Screening
Costs
$87,100
$1,142,272

USA
Screening
Costs

Initial
Screening
Costs

$210.95

$91,250
$1,082,152

USA
Screening
Costs

Initial
Screening
Costs

$210.95

$95,399
$1,022,032

$152.08

Overseas
Screening
Costs
$106.00

Overseas
Screening
Costs
$82.96

Overseas
Screening
Costs
$69.13

Overseas
Screening
Costs

5700

USA
Screening
Costs

Initial
Screening
Costs
$99,549

$210.95

$961,913

USA
Screening
Costs
$210.95

Initial
Screening
Costs
$103,699
$901,793

USA
Screening
Costs
$210.95

Initial
Screening
Costs
$1,202,391

Rescreens
in USA
147.93

USA
Screening
Costs
$210.95

Rescreens
in USA

USA
Screening
Costs

295.86

$210.95

Rescreens
in USA

USA
Screening
Costs

443.79

$210.95

Rescreens
in USA
591.72

USA
Screening
Costs
$210.95

TOTAL COSTS
$118,305
$1,142,272
$1,260,577
TOTAL COSTS
$153,660
$1,082,152
$1,235,812
TOTAL COSTS
$189,015
$1,022,032
$1,211,047
TOTAL COSTS
$224,370
$961,913
$1,186,283

Rescreens
in USA
739.65

Rescreens
in USA

USA
Screening
Costs
$210.95

USA
Screening
Costs

TOTAL COSTS
$259,725
$901,793
$1,161,518
TOTAL COSTS
$1,202,391

Table 14: Costs or cost-savings at acceptance levels below 30% for Kenya and new infections
identified by time frame
Acceptance Rate New
Program

Difference from
Current Program

%
Change

5%
10%
15%
20%
25%

-$39,462
$4,025
$47,513
$91,001
$134,488

-3%
0%
4%
8%
11%

New Infections Identified
0 months1
3 months2
> 3 months3
4
75
4
8
71
4
12
67
4
17
63
3
21
59
3

1 Reflects number of new cases identified overseas at start of program
2 Reflects number of new cases identified domestically 3 months later than at the time of overseas screening than with the overseas
intervention
3 Reflects number of new cases identified longer than 3 months than at the time of overseas screening
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Table 15: Cost calculations for acceptance levels below 30% for Uganda
5%
Acceptance

People
At Start

5 yes
95 no
Total Costs

200
3800
4000

10%
Acceptance

People
At Start

10 yes
90 no
Total Costs

400
3600
4000

15%
Acceptance

People
At Start

15 yes
85 no
Total Costs

600
3400
4000

20%
Acceptance

People
At Start

20 yes
80 no
Total Costs

800
3200
4000

25%
Acceptance

People
At Start

25 yes
75 no
Total Costs

1000
3000
4000

Current
Domestic
Program
95% yes

People
At Start
3800

Overseas
Screening
Costs
$250.86

USA
Screening
Costs
$210.95

Overseas
Screening
Costs
$143.42

USA
Screening
Costs
$210.95

Overseas
Screening
Costs
$107.61

USA
Screening
Costs
$210.95

Overseas
Screening
Costs
$89.70

USA
Screening
Costs
$210.95

Overseas
Screening
Costs
$78.95

Overseas
Screening
Costs

USA
Screening
Costs

Initial
Screening
Costs
$50,172
$761,514
Initial
Screening
Costs
$57,368
$721,435
Initial
Screening
Costs
$64,563
$681,355
Initial
Screening
Costs
$71,759
$641,275

$210.95

Initial
Screening
Costs
$78,955
$601,196

USA
Screening
Costs
$210.95

Initial
Screening
Costs
$801,594

Rescreens
in USA
39

Rescreens
in USA
79

Rescreens
in USA
118

Rescreens
in USA
158

Rescreens
in USA
197

Rescreens
in USA

USA
Screening
Costs
$210.95

USA
Screening
Costs
$210.95

USA
Screening
Costs
$210.95

USA
Screening
Costs
$210.95

USA
Screening
Costs
$210.95

USA
Screening
Costs

TOTAL
COSTS
$58,494
$761,514
$820,008
TOTAL
COSTS
$74,011
$721,435
$795,445
TOTAL
COSTS
$89,528
$681,355
$770,883
TOTAL
COSTS
$105,045
$641,275
$746,320
TOTAL
COSTS
$120,562
$601,196
$721,757
TOTAL
COSTS
$801,594

Table 16: Additional costs or cost savings for acceptance levels below 30% for Uganda and new
infections identified by time frame

Acceptance Rate
New Program
5%
10%
15%
20%
25%

Difference From
Current Program
‐$18,414
$6,149
$30,711
$55,274
$79,837

% Change
‐2%
1%
4%
7%
10%

New Infections Identified
0 months1 3 months2 > 3 months3
18
325
17
36
308
16
54
291
15
72
274
14
90
257
14

1 Reflects number of new cases identified overseas at start of program
2 Reflects number of new cases identified domestically 3 months later than at the time of overseas screening than
with the overseas intervention
3 Reflects number of new cases identified longer than 3 months than at the time of overseas screening
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Assessment of the Potential Health Benefits for the Proposed Intervention
The proposed overseas HIV screening intervention, at acceptance levels of 30% (Option 1) and
70% (Option 2), could lead to earlier HIV diagnosis and linkage to care and treatment for more U.S.bound refugees. This earlier linkage to care will likely result in increased life expectancy (extended by up
to 13 years) and quality of life; delayed onset of AIDS and opportunistic infections; and reduced
transmission of HIV. Potential life-years saved (Table 17) and deaths averted over 3 years (Table 18)
could also be realized through the proposed overseas HIV screening intervention.
These benefits could be magnified by differences in risk factors for transmission, stage of
diagnosis, and adherence to treatment in refugees compared to U.S.-born populations. According to the
literature, early HIV treatment can reduce the risk of sexual transmission, in heterosexual couples, to an
uninfected partner by 96%. Based on the literature reviewed, heterosexual transmission is a higher risk
factor in African-born and refugee populations versus U.S.-born populations. Given this pertinent
difference in risk factors for HIV transmission, early diagnosis and treatment of new HIV infections in
refugee populations may have a greater effect on reducing transmission than on U.S.-born populations.
Further, there may also be an effect of reducing the incidence of mother-child transmission of HIV.
Table 17: Estimated new infections identified earlier and life-years saved for the proposed
intervention by refugee population
Refugee Population and Overseas
Intervention Option

> 3 months3

Number of New
Infections
Diagnosed Earlier

Potential
Life Years
Saved4

409
175
585

22
9
31

185
431
N/A

2,400
5,601
N/A

512
219
732

27
12
39

231
539
N/A

3,004
7,008
N/A

745
319
1,064

39
17
56

336
784
N/A

4,368
10,192
N/A

1,043
447
1,490

55
24
78

470
1,098
N/A

6115
14,269
N/A

New Infections Identified
0 months1

3 months2

Three Country Total (Uganda, Ethiopia, and Kenya)
Option 1
185
Option 2
431
Current Program
0
Sub-Saharan Africa
Option 1
231
Option 2
539
Current Program
0
US Refugee Admissions Program (USRAP)
Low Range
Option 1
336
Option 2
784
Current Program
0
High Range
Option 1
470
Option 2
1,098
Current Program
0

1 Reflects number of new cases identified overseas at start of program
2 Reflects number of new cases identified domestically 3 months later than at the time of overseas screening than
with the overseas intervention
3 Reflects number of new cases identified longer than 3 months than at the time of overseas screening
4 Early linkage to treatment can extend the life of HIV positive individuals by up to 13 to 14 additional years
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Table 18: Estimated deaths averted over 3 years by diagnosing 60 new infections by refugee
population

Refugee Population and Overseas Intervention Option
Three Country Total (Uganda, Ethiopia, and Kenya)
Option 1
Option 2
Sub‐Saharan Africa
Option 1
Option 2
US Refugee Admissions Program (USRAP)
Low Range
Option 1
Option 2
High Range
Option 1
Option 2

Number of
New Infections
Diagnosed

Deaths Averted
Over 3 Years

185
431

62
144

231
539

77
180

336
784

112
261

470
1,098

261
366
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Limitations
Several limitations exist in completing this study. First, the prevalence data for refugees used for
this study from 2009 is outdated and may not accurately reflect current prevalence in U.S.-bound refugee
populations. Second, the HIV screening cost data for the U.S. is based on estimates for billing codes
most often used by medical practices and not specific to refugee population screening costs. Some
states, like New York, receive a flat-rate-per refugee for medical screening during the first nine months.
This may not be as comparable as actual cost data from the government perspective for refugee-related
HIV screening in the U.S. Third, cost and prevalence data for overseas screening was averaged based
on the actual IOM data for the three pilot countries to estimate results for sub-Saharan Africa and the
USRAP. Averages from the three countries may not be generalizable to the larger refugee populations.
Fourth, the “opt-in” voluntary screening approach used in the proposed intervention may result in lower
acceptance rates, so the results for Option 2 (70% acceptance rate) may be over-estimates. Fifth, the
limited research available on the specific health benefits of HIV screening in refugees makes it difficult to
correctly estimate the health impact of the proposed intervention on refugees bound for the U.S.
Despite the limitations of this study, it provides unique information that can be used by the DGMQ
at CDC to support increased budget requests to provide HIV screening for refugees while they are still
overseas. Like any other government organization, funding requests must be supported by evidence of
both effectiveness and thrift. As our results show, early HIV screening is good medicine for refugees and
saves government dollars.
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CONCLUSIONS
This study estimates and compares the costs associated with an overseas voluntary HIV
screening and treatment program for refugees undergoing resettlement to the U.S. and the current
domestic screening program after arrival in the U.S. The results suggest that HIV screening for refugees
overseas will be less expensive for the U.S. government than domestic screening and early screening will
have positive effect on public health outcomes for refugees and receiving communities. Initiating the
proposed intervention, at either acceptance level analyzed, should provide significant cost-savings to the
U.S. government each year. At the prevalence rates estimated for each of the sub-populations of
refugees they would all be considered high risk by the CDC and would justify routine and annual
screening for HIV.
Increasing the rates of overseas screening should increase rates of earlier screening and linkage
to care. Early screening and linkage to care is in line with both the U.S. National HIV Strategy and
UNHCR recommendations, resulting in positive health benefits to U.S.-bound refugees and the receiving
communities. For U.S.-bound refugees, health benefits of implementing the proposed overseas
intervention would include increased life expectancy and quality of life; delayed onset of AIDS and
opportunistic infections; and reduced transmission of HIV.
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RECOMMENDATIONS
Based on the results of this study, several recommendations are suggested for CDC to consider
in moving forward with implementation of the proposed intervention to improve acceptance of HIV
screening overseas in refugees bound for the U.S. The recommendations are consistent with the results
of other refugee health interventions that have been implemented in refugee populations resulting in
significant cost-savings for the U.S. governments. A few significant examples are described below.


Revised TB Screening and Treatment Program for U.S.-bound Immigrants and Refugees:
CDC implemented revised CDC TB screening and treatment requirements using directly
observed therapy for refugee and immigrants, resulting in more than 1,000 cases of TB
diagnosed and treated overseas prior to arrival in the U.S. and $15 to 25 million in cost-savings to
the U.S. health care system each year (CDC, 2013e).



A Pilot Vaccination Program for U.S.-bound Refugees: A vaccination program was
implemented for 50,000 out of 70,000 U.S. bound refugees annually against 10 diseases with 9
vaccines for refugees resettling from 5 pilot countries (Ethiopia, Kenya, Malaysia, Nepal, and
Thailand). A cost analysis of one measles importation in Kentucky found that the total event
costs (medical and public health response) from one imported case of measles in a refugee was
$25,000 (Coleman et. al, 2012). The cost benefit analysis found that the cost of vaccinating 1,500
refugees overseas would yield a potential return on investment of 490% (Coleman et. al, 2012).



Mass Drug Administration Programs for Parasitic Infections and Malaria: A drug program
has been implemented to provide presumptive therapy for U.S. bound refugees, resulting in
refugees being 90% less likely to have Ascaris or hookworm. This $5.1 million presumptive
treatment program for intestinal parasites from 1999 to 2010 averted an estimated 5,500 cases
and saved up to $92.1 million in U.S. health care costs (Swanson et. al, 2012; Unpublished CDC
Data, 2015). A $2.1 million presumptive treatment program for malaria in Africa from 1999 to
2010 averted an estimated 4,800 cases and saved approximately $11.2 million in potential U.S.
health care costs (Collinet-Adler et. al, 2007; Unpublished CDC Data, 2015).
In addition to results of implemented refugee health interventions, a cost benefit analysis was

completed for overseas hepatitis B virus screening. The net benefit depends on the percentage of
refugees that receive post-arrival screening and length of follow-up considered. After 10 years, if 50% of
refugees were screened in the US in the ‘Vaccinate only’ policy, the ‘Screen and vaccinate’ policy would
provide an estimated net benefit of $450 million over the ten-year period for a cohort of 58,538 refugees
compared to the ‘Vaccinate only’ policy (Jazwa et. al, 2015). This is due primarily to benefits of early
diagnosis and treatment.
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The results of this study are in line with other interventions that have been successful in
identifying and treating more refugees overseas, prior to arrival in the U.S., and providing significant costsavings to the U.S. government in the process. The recommendations presented below aim to help CDC
gain the health and cost benefits from implementing the proposed HIV screening intervention overseas.
The recommendations include educating critical partners, implementing a pilot program, expanding the
current analysis to include treatment costs, standardizing reporting of refugee health data, and
determining ways to obtain more recent refugee prevalence data for further analysis.
1) Disseminate study results to educate critical internal and external partners in refugee
resettlement and public health on the cost and health benefits for the proposed overseas
HIV screening intervention compared to the current domestic program.


Internal partners include CDC leadership, the CDC Washington Office (CDC-W), and the
Office of Financial Resources (OFR).
o

CDC leadership’s understanding of the potential cost and health benefits of the
proposed intervention may be critical in moving forward with implementing a pilot
program and potential expansion to the entire USRAP.

o

CDC leadership could assist with finding funds to begin a pilot intervention and
encouraging other Federal partner agencies to assist with these efforts.

o

CDC-W and OFR can assist with strategies to secure short- and long-term
resources to pilot the proposed overseas HIV screening intervention.



External partners include federal partners (e.g., PRM, ORR, and DHS) and non-federal
partners (e.g., state refugee health coordinators, ASTHO, NACCHO, CSTE, and
voluntary agencies for refugee resettlement).
o

Federal partners that work together in refugee resettlement efforts have different
missions, but have a shared interest in addressing infectious diseases in
refugees resettling to the U.S. Education of these partners will help encourage
support in implementing the proposed intervention and potential opportunities to
share resources to move this proposed intervention towards implementation.
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o

Non-federal partners will be essential for state and local public health and
refugee resettlement support of increasing HIV screening efforts overseas.

2) Implement a pilot intervention, with evaluation plan, in the three countries analyzed,
Uganda, Ethiopia, and Kenya, to determine feasibility and further evaluate costs and
benefits of the proposed overseas HIV screening intervention.


A pilot intervention would allow CDC to evaluate the costs and benefits of the proposed
intervention based on real time and accurate information to:
o

Identify unanticipated implementation challenges and adjustments needed for
further roll-out of the intervention to a wider refugee population (e.g., SubSaharan Africa or USRAP).

o

Identify strategies to work with local communities to plan and execute
implementation to reduce or address possible unanticipated consequences
related to HIV stigma.

o

Determine more accurate prevalence and acceptance rates and the resources
required to better estimate the benefits (e.g., costs and health), feasibility, and
resources needed to continue and/or expand the intervention.

o

Refine evaluation plans to ensure program success can be measured to
determine the expected outcomes are being met.

3) Expand analysis to include treatment costs to identify the full cost-benefits of
implementing the proposed intervention.


Like HIV screening, HIV treatment costs are likely to be much less expensive overseas
than in the U.S. The cost per year cited for HIV treatment is $23,000, so the additional
savings could be substantial. Including an analysis of the estimated savings for initiating
treatment at least three months earlier overseas would provide a fuller picture of the
potential cost-benefits for the proposed intervention.
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4) Develop standardized state reporting of U.S. bound refugee health data.


Currently refugee health data in the U.S. is collected at the state level, but a current
system does not exist for standard reporting to CDC. Lack of standard reporting makes it
difficult for CDC to make recommendations to improve refugee health programs and
interventions, both overseas and domestically.

5) Determine ways to obtain more recent prevalence data for U.S.-bound refugee populations
in the USRAP to better analyze the potential cost and health benefits of implementing the
proposed intervention.


More recent data would allow for a more accurate analysis to provide better estimates of
the potential cost-savings and health benefits for implementing the proposed intervention
in specific refugee populations and the entire USRAP.
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